Amar Anand, MD
Neurology · Vallejo
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 11
- 3 carriers
- Office
- 1
- Since medical school
- 13 years
- Graduated 2013
Offices
1 location · Integrated Neurology and Pain Management PC · 2 clinicians in this group
Hospitals listed: John Muir Medical Center - Walnut Creek Campus · Providence Queen of the Valley Medical Center · Sutter Solano Medical Center. That is not proof they admit you there this week.
Plans that list them
11 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Anand’s office at (707) 980-6636 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
11 of 11 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A149857 · Current
Licensed to practise in California · since 2017 · expires 2028-12-31 · St. George'S University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- John Muir Medical Center - Walnut Creek CampusWalnut Creek, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 2.01 (1.17 to 2.85) · 2,206 cases, Jul 2022 – Jun 2024Worse than the national rate — Death rate among surgical inpatients with serious treatable complications: 222.42 (177.82 to 267.02) · 120 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.4 (0.91 to 1.9) · 9,764 cases, Jul 2022 – Jun 2024Worse than the national rate — SSI - Colon Surgery: 2.734, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.536, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.341, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.455, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.245, Oct 2024 – Sep 2025
- Providence Queen of the Valley Medical CenterNapa, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.107, Oct 2024 – Sep 2025
- Sutter Solano Medical CenterVallejo, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 61% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.272, Oct 2024 – Sep 2025
See every measure and the patient survey for John Muir Medical Center - Walnut Creek Campus
Behind the star rating — Deaths: 3 better, 2 the same, 2 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 3 better, 5 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 2.01 (1.17 to 2.85) · 2,206 cases | Worse | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 222.42 (177.82 to 267.02) · 120 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.4 (0.91 to 1.9) · 9,764 cases | Worse | Jul 2022 – Jun 2024 |
| SSI - Colon SurgeryInfections | 2.734 | Worse | Oct 2024 – Sep 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.536 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.341 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.455 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.245 | Better | Oct 2024 – Sep 2025 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.87 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 131 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 695 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.5 · 827 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.1 · 509 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 4,483 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.35 (0.18 to 0.53) · 11,630 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.05 to 0.39) · 11,793 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.69 to 4.96) · 3,268 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.37 (0 to 2.94) · 1,631 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.76 (1.43 to 4.09) · 3,066 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.12 (0.22 to 12.02) · 1,580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.43 (1.21 to 7.64) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 685 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 615 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.88 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 93 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 729 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.1 · 91 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13 · 736 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 34.8 · 842 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 818 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.4) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.2 to 15.5) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 584 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 139 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.9) · 222 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 321 cases | No different | Jan 2024 – Dec 2024 |
What patients said (758 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Providence Queen of the Valley Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 2 better, 9 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.107 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0 to 1.92) · 609 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.5 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 191.43 (130.54 to 252.33) · 39 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12 · 271 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.7 · 376 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11 · 175 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 1,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.41) · 4,152 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.43) · 4,188 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.81 (1.63 to 5.99) · 803 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.21) · 250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.19 (0.62 to 3.77) · 742 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.45 (0.91 to 16) · 250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.58 (1.75 to 9.42) · 250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.65 (0.17 to 3.13) · 152 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.19 (0 to 0.94) · 2,994 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.684 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.887 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 133 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 270 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -4.8 · 143 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.1 · 316 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -1 · 399 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 20.4 · 337 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.5 to 7.8) · 107 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (9.8 to 17.7) · 107 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 76 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.4 to 16.2) · 848 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 423 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 40% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for Sutter Solano Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 8 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.272 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.93 (0 to 1.95) · 374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.6 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 162.36 (106.6 to 218.11) · 31 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.3 · 77 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.9 · 28 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 113 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.2 · 154 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 65 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 960 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.41) · 2,268 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 2,327 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.7 (0.38 to 5.03) · 594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 285 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.13 (0.47 to 3.78) · 581 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.1 (0 to 16.32) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.77 (3.74 to 11.8) · 275 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.21 to 3.24) · 114 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.59 (0 to 1.48) · 1,998 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.8 · 171 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 0.8 · 131 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 33 · 162 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18 · 160 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.6 to 8.5) · 42 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10 (6.8 to 14.4) · 42 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.7 · 165 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 76 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.6 to 18.9) · 322 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.8 to 1.6) · 84 cases | No different | Jan 2024 – Dec 2024 |
What patients said (355 patients answered, 17% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 63% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 61% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$389,734
Medicare paid this office $389,734 for 548 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Ultrasound of within the brain blood flow following medication | 169 | $45,237 | $263 |
| Short return visit (20+ min) | 303 | $41,777 | $75 |
| Return visit (30+ min) | 256 | $37,990 | $104 |
| Complete ultrasound of within the brain blood flow | 169 | $34,211 | $200 |
| Ultrasound of within the brain blood flow for blood clots | 167 | $25,348 | $149 |
See all 34 services
| Ultrasound of within the brain blood flow following medication | 169 | $45,237 | $263 |
| Short return visit (20+ min) | 303 | $41,777 | $75 |
| Return visit (30+ min) | 256 | $37,990 | $104 |
| Complete ultrasound of within the brain blood flow | 169 | $34,211 | $200 |
| Ultrasound of within the brain blood flow for blood clots | 167 | $25,348 | $149 |
| Ultrasound of both sides of head and neck blood flow | 161 | $22,796 | $139 |
| New patient visit (45+ min) | 140 | $18,310 | $131 |
| New patient visit (60+ min) | 100 | $18,203 | $182 |
| Ultrasound of within the brain blood flow for blood clots with microbubble injection | 118 | $17,694 | $149 |
| Injection of anesthetic agent and/or steroid into face nerve | 52 | $15,316 | $132 |
| Measurement of brain wave activity (eeg), awake and drowsy | 28 | $10,369 | $370 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 60 | $6,734 | $57 |
| Ultrasound of within the brain blood flow | 53 | $6,439 | $121 |
| Evaluation of neuropsychological test, first hour | 55 | $6,311 | $105 |
| Test for abnormal eye movement using a rotating chair | 50 | $6,189 | $124 |
| Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | 64 | $6,099 | $47 |
| Administration of psychological or neuropsychological test by technician, each additional 30 minutes | 115 | $5,176 | $34 |
| Long return visit (40+ min) | 28 | $4,897 | $144 |
| Evaluation and testing for balance with recording | 49 | $4,471 | $91 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 22 | $4,464 | $58 |
| Punch biopsy, first skin growth | 37 | $4,183 | $113 |
| Punch biopsy, each additional skin growth | 37 | $3,884 | $53 |
| Administration of psychological or neuropsychological test by technician, first 30 minutes | 115 | $3,861 | $32 |
| Telephone medical discussion with physician, 11-20 minutes | 30 | $2,604 | $70 |
| New patient visit (30+ min) | 24 | $2,118 | $88 |
| Test for balance and posture | 50 | $1,992 | $40 |
| Injection of trigger points, 1-2 muscles | 48 | $1,841 | $23 |
| Test to assess balance during warm or cool irrigation in both ears | 45 | $849 | $19 |
| Injection of trigger points, 3 or more muscles | 25 | $797 | $27 |
| Injection of drug or substance under skin or into muscle | 31 | $604 | $12 |
| Use of electrodes during balance testing | 50 | $508 | $10 |
| Telephone medical discussion with physician, 5-10 minutes | 11 | $469 | $43 |
| Injection, magnesium sulfate, per 500 mg | 22 | $128 | None |
| Injection, methylprednisolone acetate, 40 mg | 13 | $71 | None |
Procedures Medicare counted
| Skin biopsy | 90 | More than 75% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of anesthetic agent and/or steroid into face nerve | – | 81 | 373 | 336 | 181 | 116 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | – | 79 | 345 | 329 | 188 | 118 |
| Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | – | 75 | 326 | 309 | 171 | 129 |
| Injection of trigger points, 1-2 muscles | – | 56 | 326 | 309 | 160 | 81 |
| Punch biopsy, each additional skin growth | – | – | – | – | 28 | 73 |
| Punch biopsy, first skin growth | – | – | – | – | 14 | 37 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
548 Original Medicare patients in 2024. Average age 73 · Under 65 13% · 85 and older 12% · Women 56% · Also on Medicaid 38% · Health risk score 1.51. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 73% · Stroke 45% · Diabetes 33% · Depression 31% · Chronic kidney disease 26% · Coronary heart disease 21% · Atrial fibrillation 19% · Dementia 17% · Cancer 14% · Heart failure 13% · COPD 13%.
The office billed $1,475,847, Medicare allowed $505,550 and paid $389,734; for 8,004 services of 47 kinds; $21,154 of it was for drugs given in the office and $368,581 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 548 | 8,004 | 73 | 1.51 | $1,475,847 | $389,734 |
| 2023 | 411 | 5,838 | 73 | 1.62 | $1,351,739 | $369,969 |
| 2022 | 410 | 5,533 | 73 | 1.53 | $1,734,769 | $470,281 |
| 2021 | 351 | 10,020 | 74 | 1.50 | $1,785,332 | $472,752 |
| 2020 | 222 | 2,982 | 72 | 1.62 | $664,617 | $186,254 |
| 2019 | 27 | 55 | 68 | 1.22 | $15,155 | $5,077 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 29 services
| Ultrasound of within the brain blood flow following medication | 196 | $54,611 | $277 |
| Complete ultrasound of within the brain blood flow | 196 | $41,701 | $212 |
| Return visit (30+ min) | 203 | $32,029 | $106 |
| Ultrasound of within the brain blood flow for blood clots | 196 | $30,693 | $156 |
| Short return visit (20+ min) | 206 | $29,919 | $76 |
| Ultrasound of both sides of head and neck blood flow | 196 | $29,438 | $149 |
| Injection of anesthetic agent and/or steroid into face nerve | 57 | $22,839 | $126 |
| New patient visit (60+ min) | 105 | $18,525 | $176 |
| Ultrasound of within the brain blood flow for blood clots with microbubble injection | 105 | $15,836 | $151 |
| Ultrasound of within the brain blood flow | 105 | $13,431 | $128 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 63 | $10,423 | $55 |
| Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | 65 | $8,251 | $48 |
| Long return visit (40+ min) | 51 | $7,881 | $149 |
| New patient visit (45+ min) | 53 | $7,108 | $134 |
| Telephone medical discussion with physician, 11-20 minutes | 69 | $6,436 | $78 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 13 | $4,754 | $64 |
| Injection of trigger points, 1-2 muscles | 60 | $3,781 | $24 |
| Test for abnormal eye movement using a rotating chair | 30 | $3,540 | $118 |
| Evaluation and testing for balance with recording | 30 | $2,898 | $97 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,501 | $147 |
| Punch biopsy, first skin growth | 14 | $1,763 | $126 |
| Punch biopsy, each additional skin growth | 14 | $1,645 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,211 | $110 |
| Test to assess balance during warm and cool irrigation in both ears | 29 | $1,046 | $36 |
| Test for balance and posture | 22 | $960 | $44 |
| Injection of drug or substance under skin or into muscle | 44 | $809 | $12 |
| Injection, methylprednisolone acetate, 40 mg | 45 | $407 | None |
| Use of electrodes during balance testing | 30 | $320 | $11 |
| Injection, magnesium sulfate, per 500 mg | 13 | $177 | None |
2022: 27 services
| Ultrasound of within the brain blood flow following medication | 225 | $62,646 | $275 |
| Complete ultrasound of within the brain blood flow | 225 | $48,381 | $213 |
| Injection of anesthetic agent and/or steroid into face nerve | 84 | $45,330 | $135 |
| Short return visit (20+ min) | 227 | $39,527 | $77 |
| Return visit (30+ min) | 202 | $38,082 | $107 |
| Ultrasound of both sides of head and neck blood flow | 223 | $34,457 | $152 |
| Ultrasound of within the brain blood flow for blood clots | 224 | $34,432 | $151 |
| Ultrasound of within the brain blood flow for blood clots with microbubble injection | 137 | $22,241 | $159 |
| New patient visit (60+ min) | 113 | $20,178 | $179 |
| Ultrasound of within the brain blood flow | 139 | $18,524 | $131 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 91 | $17,739 | $54 |
| Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | 92 | $15,021 | $49 |
| New patient visit (45+ min) | 67 | $8,515 | $127 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 31 | $8,364 | $67 |
| Test for abnormal eye movement using a rotating chair | 66 | $8,258 | $125 |
| Long return visit (40+ min) | 45 | $8,107 | $153 |
| Injection of trigger points, 1-2 muscles | 92 | $7,469 | $24 |
| Evaluation and testing for balance with recording | 66 | $6,796 | $103 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $5,173 | $167 |
| Telephone medical discussion with physician, 11-20 minutes | 53 | $4,669 | $78 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $3,067 | $114 |
| Test for balance and posture | 61 | $2,791 | $46 |
| Test to assess balance during warm and cool irrigation in both ears | 66 | $2,497 | $38 |
| Injection of drug or substance under skin or into muscle | 79 | $2,480 | $13 |
| Injection, methylprednisolone acetate, 40 mg | 78 | $1,400 | None |
| Use of electrodes during balance testing | 66 | $704 | $11 |
| Injection, magnesium sulfate, per 500 mg | 30 | $281 | None |
2021: 26 services
| Ultrasound of within the brain blood flow following medication | 213 | $62,867 | $272 |
| Complete ultrasound of within the brain blood flow | 213 | $50,643 | $218 |
| Return visit (30+ min) | 211 | $50,621 | $113 |
| Injection of anesthetic agent and/or steroid into face nerve | 88 | $49,186 | $132 |
| Ultrasound of within the brain blood flow for blood clots | 213 | $36,552 | $158 |
| Ultrasound of both sides of head and neck blood flow | 209 | $35,356 | $156 |
| New patient visit (60+ min) | 127 | $24,346 | $192 |
| Long return visit (40+ min) | 107 | $22,827 | $159 |
| Short return visit (20+ min) | 151 | $21,425 | $81 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 94 | $20,596 | $60 |
| Ultrasound of within the brain blood flow for blood clots with microbubble injection | 119 | $19,636 | $158 |
| Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | 95 | $15,913 | $49 |
| Ultrasound of within the brain blood flow | 107 | $14,545 | $130 |
| Injection of trigger points, 1-2 muscles | 95 | $8,083 | $25 |
| New patient visit (45+ min) | 53 | $7,594 | $143 |
| Test for abnormal eye movement using a rotating chair | 45 | $5,477 | $119 |
| Evaluation and testing for balance with recording | 45 | $4,699 | $102 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,760 | $171 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $3,474 | $116 |
| Injection of drug or substance under skin or into muscle | 80 | $3,388 | $13 |
| Injection, methylprednisolone acetate, 40 mg | 94 | $2,650 | None |
| Test to assess balance during warm and cool irrigation in both ears | 45 | $1,778 | $39 |
| Test for balance and posture | 38 | $1,741 | $46 |
| Telephone medical discussion with physician, 11-20 minutes | 11 | $1,090 | $84 |
| Use of electrodes during balance testing | 45 | $465 | $10 |
| Injection, ropivacaine hydrochloride, 1 mg | 48 | $314 | None |
2020: 18 services
| Ultrasound of within the brain blood flow following medication | 116 | $32,134 | $266 |
| Complete ultrasound of within the brain blood flow | 116 | $26,846 | $224 |
| Return visit (30+ min) | 126 | $22,409 | $96 |
| Ultrasound of within the brain blood flow for blood clots | 116 | $20,633 | $171 |
| Ultrasound of both sides of head and neck blood flow | 118 | $19,990 | $164 |
| Injection of anesthetic agent and/or steroid into face nerve | 35 | $10,019 | $124 |
| New patient visit (60+ min) | 48 | $8,681 | $181 |
| Long return visit (40+ min) | 47 | $7,777 | $123 |
| New patient visit (45+ min) | 47 | $6,936 | $148 |
| Ultrasound of within the brain blood flow for blood clots with microbubble injection | 38 | $6,596 | $174 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,971 | $178 |
| Injection of anesthetic agent and/or steroid into other nerve or branch | 41 | $4,910 | $62 |
| Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | 39 | $3,632 | $48 |
| Short return visit (20+ min) | 15 | $2,276 | $71 |
| Injection of trigger points, 1-2 muscles | 32 | $1,508 | $27 |
| Injection, methylprednisolone acetate, 40 mg | 43 | $523 | None |
| Injection of drug or substance under skin or into muscle | 13 | $200 | $13 |
| Injection, ropivacaine hydrochloride, 1 mg | 28 | $86 | None |
2019: 1 service
| Return visit (30+ min) | 12 | $959 | $80 |
Medicaid work
$36,835 in 2024
Medicaid paid $36,835 for 720 billed services this clinician did in 2024, up to 57 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 363 | $8,437 |
| Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve | 70 | $5,408 |
| New patient visit (45+ min) | 64 | $4,740 |
| Injection(s), anesthetic agent(s) and/or steroid; other peripheral nerve or branch | 64 | $4,498 |
| Injection(s), anesthetic agent(s) and/or steroid; trigeminal nerve, each branch (ie, ophthalmic, maxillary, mandibular) | 52 | $4,437 |
| Return visit (30+ min) | 82 | $3,201 |
| TRANSCRANIAL DOPPLER STDY INTRACRANIAL ART COMPL | 12 | $3,092 |
| Transcranial Doppler study of the intracranial arteries; venous-arterial shunt detection with intravenous microbubble injection | 13 | $3,022 |
| 2024 | 720 | 8 | 57 | $36,835 |
| 2023 | 1,904 | 12 | 33 | $121,506 |
| 2022 | 2,323 | 13 | 37 | $165,822 |
| 2021 | 1,477 | 13 | 28 | $84,905 |
See the largest Medicaid services in earlier years
2023
| Injection(s), anesthetic agent(s) and/or steroid; other peripheral nerve or branch | 285 | $27,113 |
| Injection(s), anesthetic agent(s) and/or steroid; trigeminal nerve, each branch (ie, ophthalmic, maxillary, mandibular) | 264 | $25,314 |
| Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve | 286 | $22,140 |
| Return visit (30+ min) | 284 | $12,672 |
| Injection(s); single or multiple trigger point(s), 1 or 2 muscle(s) | 277 | $9,022 |
| Short return visit (20+ min) | 342 | $8,740 |
| TRANSCRANIAL DOPPLER STDY INTRACRANIAL ART COMPL | 29 | $6,480 |
| New patient visit (60+ min) | 27 | $2,624 |
| Transcranial Doppler study of the intracranial arteries; emboli detection without intravenous microbubble injection | 12 | $2,137 |
| Transcranial Doppler study of the intracranial arteries; vasoreactivity study | 12 | $2,051 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 71 | $1,780 |
| New patient visit (45+ min) | 15 | $1,433 |
2022
| Injection(s), anesthetic agent(s) and/or steroid; trigeminal nerve, each branch (ie, ophthalmic, maxillary, mandibular) | 313 | $32,762 |
| Injection(s), anesthetic agent(s) and/or steroid; other peripheral nerve or branch | 330 | $28,258 |
| Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve | 330 | $23,145 |
| Transcranial Doppler study of the intracranial arteries; vasoreactivity study | 54 | $12,140 |
| TRANSCRANIAL DOPPLER STDY INTRACRANIAL ART COMPL | 54 | $10,894 |
| Injection(s); single or multiple trigger point(s), 1 or 2 muscle(s) | 333 | $9,970 |
| Transcranial Doppler study of the intracranial arteries; emboli detection without intravenous microbubble injection | 41 | $9,537 |
| Short return visit (20+ min) | 377 | $9,331 |
| Return visit (30+ min) | 197 | $8,880 |
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 54 | $8,519 |
| Transcranial Doppler study of the intracranial arteries; venous-arterial shunt detection with intravenous microbubble injection | 24 | $6,267 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 201 | $4,658 |
2021
| Injection(s), anesthetic agent(s) and/or steroid; trigeminal nerve, each branch (ie, ophthalmic, maxillary, mandibular) | 191 | $14,934 |
| Injection(s), anesthetic agent(s) and/or steroid; other peripheral nerve or branch | 201 | $11,558 |
| Injection(s), anesthetic agent(s) and/or steroid; greater occipital nerve | 205 | $10,283 |
| Transcranial Doppler study of the intracranial arteries; vasoreactivity study | 53 | $10,107 |
| Transcranial Doppler study of the intracranial arteries; emboli detection without intravenous microbubble injection | 54 | $9,479 |
| TRANSCRANIAL DOPPLER STDY INTRACRANIAL ART COMPL | 53 | $9,130 |
| DUPLEX SCAN EXTRACRANIAL ART COMPL BI STUDY | 41 | $4,785 |
| Injection(s); single or multiple trigger point(s), 1 or 2 muscle(s) | 204 | $4,397 |
| Return visit (30+ min) | 164 | $4,238 |
| Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | 187 | $2,842 |
| Short return visit (20+ min) | 99 | $2,150 |
| Transcranial Doppler study of the intracranial arteries; venous-arterial shunt detection with intravenous microbubble injection | 12 | $908 |
Drugs they prescribed that Part D paid
$231,748
Pharmacies billed $231,748 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,556 generic and fewer than 11 brand-name prescriptions · $231,748 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Nurtec Odt | None | 47 | $56,185 | $1,195 |
| Nayzilam | None | 38 | $22,104 | $582 |
| Eliquis | None | 15 | $14,599 | $973 |
| Aimovig | Migraine | 20 | $14,286 | $714 |
| Qulipta | None | 12 | $13,133 | $1,094 |
See all 38 drugs
| Nurtec Odt | None | 47 | $56,185 | $1,195 |
| Nayzilam | None | 38 | $22,104 | $582 |
| Eliquis | None | 15 | $14,599 | $973 |
| Aimovig | Migraine | 20 | $14,286 | $714 |
| Qulipta | None | 12 | $13,133 | $1,094 |
| Ajovy | None | 12 | $8,053 | $671 |
| Memantine | None | 101 | $5,458 | $54 |
| Divalproex | None | 29 | $5,181 | $179 |
| Gabapentin | None | 122 | $3,880 | $32 |
| Prazosin | None | 28 | $3,520 | $126 |
| Amitriptyline | None | 125 | $2,746 | $22 |
| Propranolol Hcl Er | None | 57 | $2,436 | $43 |
| Lamotrigine | None | 99 | $1,949 | $20 |
| Topiramate | None | 66 | $1,599 | $24 |
| Carbamazepine Er | None | 15 | $1,295 | $86 |
| Donepezil | None | 91 | $1,232 | $14 |
| Levetiracetam | None | 33 | $1,219 | $37 |
| Pregabalin | None | 19 | $1,150 | $61 |
| Carbidopa-Levodopa | None | 20 | $1,140 | $57 |
| Nortriptyline | None | 40 | $1,133 | $28 |
| Candesartan Cilexetil | None | 11 | $1,007 | $92 |
| Amantadine | None | 13 | $996 | $77 |
| Clopidogrel | None | 44 | $972 | $22 |
| Baclofen | None | 25 | $950 | $38 |
| Duloxetine | None | 30 | $931 | $31 |
| Mirtazapine | None | 12 | $756 | $63 |
| Sumatriptan | None | 65 | $739 | $11 |
| Sertraline | None | 96 | $738 | $8 |
| Tizanidine | None | 19 | $667 | $35 |
| Venlafaxine Hcl Er | None | 32 | $646 | $20 |
| Zonisamide | None | 18 | $606 | $34 |
| Rizatriptan | None | 36 | $569 | $16 |
| Rosuvastatin | None | 37 | $452 | $12 |
| Valproic Acid | None | 13 | $414 | $32 |
| Atorvastatin | None | 23 | $297 | $13 |
| Trazodone | None | 15 | $212 | $14 |
| Escitalopram | None | 17 | $171 | $10 |
| Cyclobenzaprine | None | 13 | $50 | $4 |
Year by year
| 2024 | 1,753 | 350 | None | None | $231,748 |
| 2023 | 1,814 | 347 | 1% (22) | None | $371,958 |
| 2022 | 1,559 | 319 | None | None | $357,471 |
| 2021 | 1,243 | 273 | 2% (25) | None | $239,528 |
| 2020 | 1,603 | 276 | 26% (410) | None | $92,300 |
| 2019 | 2,668 | 273 | 51% (1,353) | None | $157,179 |
| 2018 | 646 | 161 | 63% (407) | None | $48,567 |
| 2017 | 57 | 14 | 0% (0) | None | $35,420 |
| 2016 | 125 | 24 | 0% (0) | None | $7,638 |
| 2015 | 78 | 21 | 0% (0) | None | $2,911 |
| 2014 | 70 | 14 | None | None | $6,748 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 42 drugs
| Aimovig | Migraine | 30 | $28,914 | $964 |
| Nurtec Odt | None | 21 | $20,485 | $975 |
| Ajovy | None | 25 | $17,971 | $719 |
| Emgality | Migraine | 21 | $15,366 | $732 |
| Eliquis | None | 15 | $13,795 | $920 |
| Qulipta | None | 12 | $13,346 | $1,112 |
| Lyrica | None | 12 | $11,894 | $991 |
| Gabapentin | None | 156 | $7,350 | $47 |
| Memantine | None | 75 | $5,433 | $72 |
| Lamotrigine | None | 109 | $4,749 | $44 |
| Amitriptyline | None | 148 | $3,384 | $23 |
| Carbidopa-Levodopa | None | 42 | $3,378 | $80 |
| Propranolol Hcl Er | None | 57 | $3,359 | $59 |
| Amantadine | None | 30 | $2,970 | $99 |
| Duloxetine | None | 47 | $2,779 | $59 |
| Topiramate | None | 50 | $2,559 | $51 |
| Divalproex | None | 22 | $2,401 | $109 |
| Levetiracetam | None | 43 | $2,216 | $52 |
| Carbamazepine Er | None | 14 | $2,083 | $149 |
| Pregabalin | None | 30 | $2,078 | $69 |
| Divalproex Sodium Er | None | 12 | $2,013 | $168 |
| Nortriptyline | None | 59 | $1,862 | $32 |
| Clorazepate Dipotassium | None | 13 | $1,636 | $126 |
| Sertraline | None | 98 | $1,546 | $16 |
| Baclofen | None | 19 | $1,457 | $77 |
| Donepezil | None | 73 | $1,262 | $17 |
| Zonisamide | None | 14 | $1,083 | $77 |
| Sumatriptan | None | 51 | $950 | $19 |
| Rosuvastatin | None | 48 | $938 | $20 |
| Primidone | None | 16 | $812 | $51 |
| Candesartan Cilexetil | None | 14 | $799 | $57 |
| Clopidogrel | None | 49 | $782 | $16 |
| Rizatriptan | None | 32 | $723 | $23 |
| Diclofenac | None | 12 | $658 | $55 |
| Propranolol | None | 13 | $609 | $47 |
| Venlafaxine Hcl Er | None | 12 | $607 | $51 |
| Carbamazepine | None | 12 | $595 | $50 |
| Escitalopram | None | 29 | $569 | $20 |
| Atorvastatin | None | 35 | $440 | $13 |
| Citalopram Hbr | None | 13 | $307 | $24 |
| Naproxen | None | 11 | $36 | $3 |
| Cyclobenzaprine | None | 12 | $21 | $2 |
2022: 33 drugs
| Austedo | None | 11 | $68,263 | $6,206 |
| Aimovig | Migraine | 23 | $23,735 | $1,032 |
| Nurtec Odt | None | 15 | $14,521 | $968 |
| Ajovy | None | 17 | $12,566 | $739 |
| Emgality | Migraine | 12 | $8,291 | $691 |
| Gabapentin | None | 156 | $4,421 | $28 |
| Propranolol Hcl Er | None | 67 | $4,107 | $61 |
| Pregabalin | None | 32 | $3,792 | $119 |
| Levetiracetam | None | 41 | $3,184 | $78 |
| Carbamazepine Er | None | 23 | $3,141 | $137 |
| Amitriptyline | None | 149 | $2,943 | $20 |
| Memantine | None | 41 | $2,704 | $66 |
| Lamotrigine | None | 118 | $2,492 | $21 |
| Amantadine | None | 23 | $2,391 | $104 |
| Carbidopa-Levodopa | None | 54 | $2,275 | $42 |
| Rosuvastatin | None | 63 | $2,006 | $32 |
| Baclofen | None | 26 | $1,933 | $74 |
| Diclofenac | None | 25 | $1,504 | $60 |
| Topiramate | None | 54 | $1,498 | $28 |
| Propranolol | None | 22 | $983 | $45 |
| Sertraline | None | 70 | $913 | $13 |
| Duloxetine | None | 37 | $889 | $24 |
| Clopidogrel | None | 32 | $752 | $23 |
| Primidone | None | 15 | $737 | $49 |
| Atorvastatin | None | 47 | $696 | $15 |
| Sumatriptan | None | 34 | $670 | $20 |
| Donepezil | None | 59 | $619 | $10 |
| Escitalopram | None | 18 | $596 | $33 |
| Venlafaxine Hcl Er | None | 15 | $561 | $37 |
| Nortriptyline | None | 31 | $493 | $16 |
| Rizatriptan | None | 19 | $315 | $17 |
| Naproxen | None | 19 | $82 | $4 |
| Lorazepam | None | 14 | $16 | $1 |
2021: 33 drugs
| Aimovig | Migraine | 22 | $15,404 | $700 |
| Ajovy | None | 13 | $14,126 | $1,087 |
| Eliquis | None | 14 | $12,708 | $908 |
| Zomig | None | 13 | $11,908 | $916 |
| Nurtec Odt | None | 12 | $11,293 | $941 |
| Pregabalin | None | 33 | $8,554 | $259 |
| Emgality | Migraine | 12 | $7,914 | $659 |
| Levetiracetam | None | 34 | $4,047 | $119 |
| Gabapentin | None | 117 | $3,255 | $28 |
| Propranolol Hcl Er | None | 44 | $3,106 | $71 |
| Rosuvastatin | None | 67 | $2,497 | $37 |
| Amitriptyline | None | 119 | $1,760 | $15 |
| Primidone | None | 21 | $1,513 | $72 |
| Topiramate | None | 47 | $1,272 | $27 |
| Carbamazepine Er | None | 11 | $1,229 | $112 |
| Diclofenac | None | 15 | $1,172 | $78 |
| Baclofen | None | 16 | $1,162 | $73 |
| Memantine | None | 35 | $1,117 | $32 |
| Sumatriptan | None | 57 | $1,015 | $18 |
| Lamotrigine | None | 50 | $1,008 | $20 |
| Sertraline | None | 60 | $761 | $13 |
| Propranolol | None | 24 | $717 | $30 |
| Clopidogrel | None | 42 | $704 | $17 |
| Duloxetine | None | 12 | $526 | $44 |
| Atorvastatin | None | 40 | $497 | $12 |
| Escitalopram | None | 22 | $494 | $22 |
| Donepezil | None | 43 | $420 | $10 |
| Carbidopa-Levodopa | None | 15 | $417 | $28 |
| Nortriptyline | None | 13 | $231 | $18 |
| Trazodone | None | 12 | $159 | $13 |
| Naproxen | None | 21 | $144 | $7 |
| Rizatriptan | None | 12 | $105 | $9 |
| Metoclopramide | None | 20 | $65 | $3 |
2020: 31 drugs
| Belbuca | 18 | $10,155 | $564 |
| Zomig | 11 | $6,240 | $567 |
| Rosuvastatin | 107 | $4,874 | $46 |
| Gabapentin | 187 | $4,771 | $26 |
| Propranolol Hcl Er | 59 | $3,949 | $67 |
| Pregabalin | 39 | $3,757 | $96 |
| Hydrocodone-Acetaminophen | 202 | $2,961 | $15 |
| Amitriptyline | 129 | $1,953 | $15 |
| Morphine Sulfate Er | 77 | $1,690 | $22 |
| Oxycodone-Acetaminophen | 64 | $1,677 | $26 |
| Sumatriptan | 31 | $1,348 | $43 |
| Primidone | 19 | $1,322 | $70 |
| Baclofen | 16 | $1,179 | $74 |
| Candesartan Cilexetil | 18 | $1,151 | $64 |
| Cyclobenzaprine | 46 | $906 | $20 |
| Levetiracetam | 24 | $764 | $32 |
| Memantine | 23 | $710 | $31 |
| Lamotrigine | 39 | $573 | $15 |
| Atorvastatin | 31 | $473 | $15 |
| Topiramate | 47 | $459 | $10 |
| Nortriptyline | 33 | $393 | $12 |
| Oxycodone | 15 | $382 | $25 |
| Donepezil | 25 | $310 | $12 |
| Clopidogrel | 36 | $303 | $8 |
| Tizanidine | 16 | $233 | $15 |
| Clonazepam | 23 | $130 | $6 |
| Naproxen | 21 | $129 | $6 |
| Sertraline | 17 | $122 | $7 |
| Ibuprofen | 19 | $100 | $5 |
| Trazodone | 16 | $67 | $4 |
| Metoclopramide | 13 | $58 | $4 |
2019: 38 drugs
| Belbuca | 63 | $26,041 | $413 |
| Oxycontin | 21 | $23,667 | $1,127 |
| Lyrica | 26 | $11,197 | $431 |
| Hydrocodone-Acetaminophen | 629 | $10,395 | $17 |
| Morphine Sulfate Er | 251 | $7,364 | $29 |
| Gabapentin | 242 | $6,878 | $28 |
| Oxycodone-Acetaminophen | 227 | $6,613 | $29 |
| Rosuvastatin | 80 | $2,933 | $37 |
| Propranolol Hcl Er | 34 | $2,396 | $70 |
| Pregabalin | 25 | $2,093 | $84 |
| Amitriptyline | 98 | $1,400 | $14 |
| Fentanyl | 27 | $1,348 | $50 |
| Candesartan Cilexetil | 25 | $1,197 | $48 |
| Oxycodone | 43 | $1,020 | $24 |
| Sumatriptan | 40 | $924 | $23 |
| Primidone | 16 | $801 | $50 |
| Methadone | 36 | $680 | $19 |
| Cyclobenzaprine | 56 | $672 | $12 |
| Atorvastatin | 48 | $656 | $14 |
| Topiramate | 39 | $620 | $16 |
| Nortriptyline | 76 | $618 | $8 |
| Carbidopa-Levodopa | 16 | $578 | $36 |
| Lamotrigine | 27 | $534 | $20 |
| Clonazepam | 81 | $527 | $7 |
| Propranolol | 16 | $512 | $32 |
| Ibuprofen | 40 | $488 | $12 |
| Duloxetine | 18 | $470 | $26 |
| Tizanidine | 33 | $448 | $14 |
| Memantine | 16 | $403 | $25 |
| Celecoxib | 11 | $288 | $26 |
| Naproxen | 49 | $235 | $5 |
| Levetiracetam | 13 | $222 | $17 |
| Clopidogrel | 11 | $155 | $14 |
| Tramadol | 18 | $116 | $6 |
| Donepezil | 11 | $95 | $9 |
| Lorazepam | 21 | $45 | $2 |
| Sertraline | 15 | $38 | $3 |
| Metoclopramide | 11 | $30 | $3 |
2018: 13 drugs
| Hydrocodone-Acetaminophen | 189 | $3,206 | $17 |
| Oxycodone-Acetaminophen | 63 | $1,965 | $31 |
| Morphine Sulfate Er | 82 | $1,959 | $24 |
| Amitriptyline | 25 | $489 | $20 |
| Methadone | 20 | $412 | $21 |
| Topiramate | 13 | $310 | $24 |
| Gabapentin | 24 | $298 | $12 |
| Nortriptyline | 29 | $188 | $6 |
| Sumatriptan | 13 | $180 | $14 |
| Divalproex | 13 | $179 | $14 |
| Oxycodone | 13 | $156 | $12 |
| Clonazepam | 15 | $64 | $4 |
| Naproxen | 11 | $59 | $5 |
2017: 1 drug
| Topiramate | 13 | $222 | $17 |
2016: 4 drugs
| Levetiracetam | 24 | $1,178 | $49 |
| Gabapentin | 18 | $297 | $17 |
| Atorvastatin | 16 | $295 | $18 |
| Topiramate | 18 | $179 | $10 |
2015: 3 drugs
| Atorvastatin | 15 | $621 | $41 |
| Prednisone | 15 | $95 | $6 |
| Gabapentin | 11 | $76 | $7 |
Money from drug and device companies
$2,044 in 2025
| 2025 | 23 | 74 | None | $2,044 |
| 2024 | 15 | 66 | None | $1,528 |
| 2023 | 14 | 99 | None | $1,776 |
| 2022 | 18 | 99 | None | $2,040 |
| 2021 | 9 | 49 | None | $900 |
| 2020 | 3 | 29 | None | $557 |
| 2019 | 4 | 7 | None | $196 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Neurocrine BioSciences | Ingrezza | $336 | 10 payments
|
| Abbvie | Vyalev | $321 | 14 payments
|
| Otsuka America Pharmaceutical | Rexulti | $159 | 6 payments
|
| Ucb | Nayzilam | $153 | 5 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $135 | 5 payments
|
| Lundbeck | Vyepti | $123 | 2 payments
|
See all 74 published payments
| Vanda Pharmaceuticals | Meals · 2025-12-17 | Ponvory | $39 |
| Ucb | Meals · 2025-12-11 | Fintepla | $38 |
| Otsuka America Pharmaceutical | Meals · 2025-12-03 | Rexulti | $27 |
| Biogen | Meals · 2025-12-01 | Spinraza | $20 |
| Otsuka America Pharmaceutical | Meals · 2025-11-17 | Rexulti | $31 |
| Amgen | Meals · 2025-11-12 | Uplizna | $30 |
| Janssen Biotech | Meals · 2025-11-10 | None | $17 |
| Merz Pharmaceuticals | Meals · 2025-11-07 | Inbrija | $36 |
| Teva Pharmaceuticals USA | Meals · 2025-11-05 | Austedo Xr | $28 |
| Neurelis | Meals · 2025-11-03 | Valtoco | $38 |
| Neurocrine BioSciences | Meals · 2025-11-01 | Ingrezza | $38 |
| Neurocrine BioSciences | Meals · 2025-10-29 | Ingrezza | $13 |
| Abbvie | Meals · 2025-10-28 | Vyalev | $28 |
| Pfizer | Meals · 2025-10-16 | Nurtec Odt | $20 |
| Abbvie | Meals · 2025-10-14 | Vyalev | $17 |
| Amneal Pharmaceuticals | Meals · 2025-10-06 | Crexont | $17 |
| Argenx US | Meals · 2025-10-03 | Vyvgart | $26 |
| Neurocrine BioSciences | Meals · 2025-10-01 | Ingrezza | $12 |
| Neurocrine BioSciences | Meals · 2025-09-30 | Ingrezza | $29 |
| Abbvie | Meals · 2025-09-22 | Vyalev | $29 |
| Neurocrine BioSciences | Meals · 2025-09-20 | Ingrezza | $9 |
| Janssen Biotech | Meals · 2025-09-19 | None | $40 |
| Teva Pharmaceuticals USA | Meals · 2025-09-17 | Austedo Xr | $31 |
| Abbvie | Meals · 2025-09-16 | Qulipta | $21 |
| TG Therapeutics | Meals · 2025-09-10 | Briumvi | $38 |
| Otsuka America Pharmaceutical | Meals · 2025-09-05 | Rexulti | $31 |
| Genentech USA | Meals · 2025-09-03 | Ocrevus Zunovo | $19 |
| Abbvie | Meals · 2025-08-19 | Qulipta | $11 |
| Ucb | Meals · 2025-08-19 | Nayzilam | $27 |
| Pfizer | Meals · 2025-08-15 | Nurtec Odt | $18 |
| Teva Pharmaceuticals USA | Meals · 2025-08-04 | Austedo Xr | $17 |
| Abbvie | Meals · 2025-08-01 | Vyalev | $34 |
| Neurocrine BioSciences | Meals · 2025-07-28 | Ingrezza | $19 |
| Abbvie | Meals · 2025-07-23 | Vyalev | $11 |
| Abbvie | Meals · 2025-07-22 | Qulipta | $32 |
| SPR Therapeutics | Meals · 2025-07-18 | Sprint Pns System | $29 |
| Otsuka America Pharmaceutical | Meals · 2025-06-30 | Rexulti | $27 |
| MDD US Operations | Meals · 2025-06-30 | None | $17 |
| Ucb | Meals · 2025-06-19 | Nayzilam | $36 |
| Abbvie | Meals · 2025-06-17 | Qulipta | $33 |
| Neurocrine BioSciences | Meals · 2025-06-16 | Ingrezza | $111 |
| Biogen | Meals · 2025-06-12 | Skyclarys | $28 |
| Pfizer | Meals · 2025-06-09 | Nurtec Odt | $18 |
| Neurelis | Meals · 2025-06-06 | Valtoco | $32 |
| Lundbeck | Meals · 2025-05-29 | Vyepti | $28 |
| Amneal Pharmaceuticals | Meals · 2025-05-19 | Crexont | $24 |
| Pfizer | Meals · 2025-05-16 | Nurtec Odt | $22 |
| Biogen | Meals · 2025-05-03 | Skyclarys | $29 |
| Saluda Medical Americas | Meals · 2025-05-01 | Evoke | $23 |
| Abbvie | Meals · 2025-04-28 | Qulipta | $11 |
| Eisai | Meals · 2025-04-28 | Leqembi | $29 |
| Abbvie | Meals · 2025-04-15 | Qulipta | $26 |
| Lundbeck | Meals · 2025-04-09 | Vyepti | $95 |
| Otsuka America Pharmaceutical | Meals · 2025-04-04 | Rexulti | $21 |
| Pfizer | Meals · 2025-03-31 | Nurtec Odt | $22 |
| Lilly USA | Meals · 2025-03-25 | Kisunla | $26 |
| Teva Pharmaceuticals USA | Meals · 2025-03-21 | Austedo Xr | $26 |
| Abbvie | Meals · 2025-03-19 | Ubrelvy | $15 |
| Vertex Pharmaceuticals | Meals · 2025-03-17 | Journavx | $30 |
| Genentech USA | Meals · 2025-03-10 | Ocrevus | $19 |
| Neurocrine BioSciences | Meals · 2025-03-08 | Ingrezza | $40 |
| Otsuka America Pharmaceutical | Meals · 2025-03-05 | Rexulti | $22 |
| Abbvie | Meals · 2025-03-03 | Ubrelvy | $28 |
| Ucb | Meals · 2025-02-24 | Briviact | $22 |
| MDD US Operations | Meals · 2025-02-20 | None | $16 |
| MDD US Operations | Meals · 2025-02-19 | None | $17 |
| Neurocrine BioSciences | Meals · 2025-02-08 | Ingrezza | $39 |
| Teva Pharmaceuticals USA | Meals · 2025-02-05 | Ajovy | $33 |
| Biogen | Meals · 2025-02-03 | Tysabri | $14 |
| Neurelis | Meals · 2025-01-31 | Valtoco | $40 |
| Amgen | Meals · 2025-01-27 | Uplizna | $26 |
| Abbvie | Meals · 2025-01-20 | Vyalev | $25 |
| Neurocrine BioSciences | Meals · 2025-01-11 | Ingrezza | $27 |
| Ucb | Meals · 2025-01-07 | Briviact | $30 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,528
| Neurocrine Biosciences | Ingrezza | $417 | 13 payments
|
| Pfizer | Nurtec Odt | $220 | 14 payments
|
| Abbvie | Duopa | $199 | 9 payments
|
| Otsuka America Pharmaceutical | Nuedexta | $137 | 6 payments
|
| Neurelis | Valtoco | $102 | 3 payments
|
| Lilly USA | Kisunla | $87 | 4 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $84 | 4 payments
|
| Ucb | Briviact | $82 | 4 payments
|
| Amgen | Uplizna | $48 | 2 payments
|
| Celgene | Zeposia | $45 | 2 payments
|
| Amneal Pharmaceuticals | Rytary | $26 | 1 payment
|
| Vertex Pharmaceuticals | None | $24 | 1 payment
|
| Grifols USA | Gamunex-C | $24 | 1 payment
|
| Biogen | Tysabri | $17 | 1 payment
|
| Eisai | Leqembi | $15 | 1 payment
|
2023: $1,776
| Neurocrine Biosciences | Ongentys | $357 | 23 payments
|
| Pfizer | Nurtec Odt | $302 | 17 payments
|
| AbbVie | Ubrelvy | $263 | 13 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $208 | 18 payments
|
| Biogen | Vumerity | $162 | 6 payments
|
| Lilly USA | Amyvid | $129 | 6 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $77 | 3 payments
|
| Ucb | Briviact | $63 | 3 payments
|
| Horizon Therapeutics plc | Uplizna | $53 | 2 payments
|
| Kowa Pharmaceuticals America | Seglentis | $43 | 2 payments
|
| MDD US Operations | None | $39 | 2 payments
|
| Otsuka America Pharmaceutical | Nuedexta | $34 | 2 payments
|
| Argenx US | Vyvgart | $26 | 1 payment
|
| Genzyme | Aubagio | $19 | 1 payment
|
2022: $2,040
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $464 | 20 payments
|
| Teva Pharmaceuticals USA | Austedo | $334 | 14 payments
|
| Abbvie | Qulipta | $331 | 20 payments
|
| Lilly USA | Emgality | $167 | 9 payments
|
| Celgene | Zeposia | $129 | 9 payments
|
| Biogen | Tysabri | $107 | 5 payments
|
| Avanir Pharmaceuticals | Nuedexta | $83 | 3 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $79 | 4 payments
|
| Janssen Pharmaceuticals | Ponvory | $64 | 3 payments
|
| Genzyme | Aubagio | $57 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $54 | 2 payments
|
| GRT US Holding | Qutenza | $38 | 2 payments
|
| Pfizer | Octagam Immune Globulin (Human) | $33 | 1 payment
|
| Argenx US | Vyvgart | $27 | 1 payment
|
| Eisai | Fycompa | $24 | 1 payment
|
| Amgen | Aimovig | $21 | 1 payment
|
| Sunovion Pharmaceuticals | Aptiom | $16 | 1 payment
|
| Si-Bone | None | $12 | 1 payment
|
2021: $900
| Biohaven Pharmaceuticals | Nurtec Odt | $334 | 17 payments
|
| AbbVie | Ubrelvy | $276 | 18 payments
|
| Teva Pharmaceuticals USA | Ajovy | $100 | 5 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $46 | 2 payments
|
| Janssen Pharmaceuticals | Ponvory | $42 | 2 payments
|
| Amgen | Aimovig | $40 | 2 payments
|
| Allergan | Ubrelvy | $29 | 1 payment
|
| Kyowa Kirin | Nourianz | $19 | 1 payment
|
| Lilly USA | Emgality | $14 | 1 payment
|
2020: $557
| Allergan | Ubrelvy | $495 | 25 payments
|
| Collegium Pharmaceutical | Xtampza | $46 | 3 payments
|
| Teva Pharmaceuticals USA | Ajovy | $16 | 1 payment
|
2019: $196
| Teva Pharmaceuticals USA | Ajovy | $141 | 3 payments
|
| BioDelivery Sciences International | Bunavail 2.1 Mg 30-Count Box | $25 | 2 payments
|
| Collegium Pharmaceutical | Xtampza | $20 | 1 payment
|
| Electronic Waveform Lab | None | $10 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 0.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1407297005
- Licence
- CA A149857, IN 01080969A, SC LL36095California A149857: Current · expires 2028-12-31
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Neurology (2084N0400X); Federal specialty code 103TB0200X (103TB0200X); Federal specialty code 2084D0003X (2084D0003X); Federal specialty code 2084P2900X (2084P2900X)
- Mailing address
- 712 Bancroft Rd Ste 905, Walnut Creek, CA, 94598
- NPI first listed
- 2013-07-11
- NPI last updated
- 2020-10-15
- NPI record certified
- 2020-10-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1208 E 5th St Ste 300, Benicia, CA, 94510 · 8 Medical Park Ste 420, Columbia, SC, 29203 · 4770 Covert Ave Ste 101, Evansville, IN, 47714 · 109 US Highway 66 E Ste 151, Tell City, IN, 47586 · 1455 Montego, Walnut Creek, CA, 94598 · 675 Ygnacio Valley Rd, Walnut Creek, CA, 94596